General Announcement::Glenmark Pharmaceuticals receives tentative ANDA approval for Clobetasol Propionate Foam, 0.05%

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
26-Nov-2018 13:51:54
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives tentative ANDA approval for Clobetasol Propionate Foam, 0.05%
Announcement Reference
SG181126OTHRHID3
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
26/11/2018 11:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals receives tentative ANDA approval for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation)

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Attachments

SGX_PR_26112018.pdf
Total size =560K